Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma

N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with high rates of invasion and distant metastasis. This study was to explore the ability of intensity-modulated radiotherapy (IMRT) combined with chemotherapy to manage unresectable PDTC. Between February 2011 and April 2012, 5 patients with unresectable PDTC were treated by IMRT at our institution and were included in this analysis. The median radiotherapy dose to the gross tumor volume (GTV) was 66 Gy/33 fractions/6.4 weeks. All patients received chemotherapy, and one patient with tumor compression symptoms had a tracheotomy before treatment. The mean survival time of the 5 patients was 41.6 months. The direct causes of death were distant metastases (40%) and progression of the locoregional disease (20%). In conclusion, IMRT combined with chemotherapy for unresectable PDTC might be beneficial to improve locoregional control. Further new therapies are needed to control metastases.

Cite

CITATION STYLE

APA

Xue, F., Li, D., Hu, C., Wang, Z., He, X., & Wu, Y. (2017). Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma. Oncotarget, 8(9), 15934–15942. https://doi.org/10.18632/oncotarget.12785

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free